Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Urol. doi: /nrurol

Published byΚρέων Λαμπρόπουλος Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Urol. doi: /nrurol"— Presentation transcript:

1 Nat. Rev. Urol. doi:10.1038/nrurol.2016.103
Figure 3 Immunomodulatory effects of targeted therapies for renal cell carcinoma Figure 3 | Immunomodulatory effects of targeted therapies for renal cell carcinoma. Tumour cells can secrete vascular endothelial growth factor-A (VEGF-A), which, when it binds to the VEGF receptor (VEGFR), can signal to halt antigen–presenting-cell (APC) maturation. Both bevacizumab — a monoclonal antibody against VEGF-A — and sunitinib — a small-molecule tyrosine kinase inhibitor — can block signalling through this pathway and, therefore, promote maturation of APCs. Both regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) inhibit immune activation. VEGF-blockade with sunitinib or sorafenib can inhibit Treg cell function and treatment with sunitinib or axitinib has been found to inhibit function of MDSCs in preclinical and clinical models. Carlo, M. I. et. al. (2016) Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma Nat. Rev. Urol. doi: /nrurol

Download ppt "Nat. Rev. Urol. doi: /nrurol"

Similar presentations

Tyrosine kinase signalling (review) TGF signalling Notch signalling.

Tyrosine kinase signalling (review) TGF signalling Notch signalling.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.

Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Trans. Vis. Sci. Tech ;5(2):10. doi: /tvst Figure Legend:

Trans. Vis. Sci. Tech ;5(2):10. doi: /tvst Figure Legend:
Targeting HIF2α in Clear-Cell Renal Cell Carcinoma

Targeting HIF2α in Clear-Cell Renal Cell Carcinoma
Volume 76, Issue 9, Pages (November 2009)

Volume 76, Issue 9, Pages (November 2009)
Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints
Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials  Pippa Newell, Augusto Villanueva, Josep M. Llovet 

Molecular targeted therapies in hepatocellular carcinoma: From pre-clinical models to clinical trials  Pippa Newell, Augusto Villanueva, Josep M. Llovet 
Figure 1 Key elements of cancer-related inflammation

Figure 1 Key elements of cancer-related inflammation
Figure 1 Cellular processes involved in cancer development

Figure 1 Cellular processes involved in cancer development
Figure 1 Radiation-induced effects on tumour cells

Figure 1 Radiation-induced effects on tumour cells
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro
Figure 1 Induction of immune tolerance

Figure 1 Induction of immune tolerance
Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.
Figure 2 Neoantigen presentation in the tumour microenvironment

Figure 2 Neoantigen presentation in the tumour microenvironment
Figure 1 Four nodes to target when inducing anti-tumour immunity

Figure 1 Four nodes to target when inducing anti-tumour immunity
Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2
Figure 1 Current treatments for PNETs

Figure 1 Current treatments for PNETs
Figure 7 Clinical options for HCC therapy

Figure 7 Clinical options for HCC therapy
Oncology Meets Immunology: The Cancer-Immunity Cycle

Oncology Meets Immunology: The Cancer-Immunity Cycle

Similar presentations

Ads by Google